EP1254155A4 - Mob-5/hmob-5 als diagnostisches markierungsmittel - Google Patents

Mob-5/hmob-5 als diagnostisches markierungsmittel

Info

Publication number
EP1254155A4
EP1254155A4 EP01903364A EP01903364A EP1254155A4 EP 1254155 A4 EP1254155 A4 EP 1254155A4 EP 01903364 A EP01903364 A EP 01903364A EP 01903364 A EP01903364 A EP 01903364A EP 1254155 A4 EP1254155 A4 EP 1254155A4
Authority
EP
European Patent Office
Prior art keywords
hmob
mob
diagnostic marker
cancer diagnostic
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01903364A
Other languages
English (en)
French (fr)
Other versions
EP1254155A1 (de
Inventor
Peng Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of EP1254155A1 publication Critical patent/EP1254155A1/de
Publication of EP1254155A4 publication Critical patent/EP1254155A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP01903364A 2000-01-26 2001-01-26 Mob-5/hmob-5 als diagnostisches markierungsmittel Withdrawn EP1254155A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17818500P 2000-01-26 2000-01-26
US178185P 2000-01-26
PCT/US2001/002680 WO2001055170A1 (en) 2000-01-26 2001-01-26 Mob-5/hmob-5 as a cancer diagnostic marker

Publications (2)

Publication Number Publication Date
EP1254155A1 EP1254155A1 (de) 2002-11-06
EP1254155A4 true EP1254155A4 (de) 2003-06-18

Family

ID=22651551

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01903364A Withdrawn EP1254155A4 (de) 2000-01-26 2001-01-26 Mob-5/hmob-5 als diagnostisches markierungsmittel

Country Status (3)

Country Link
EP (1) EP1254155A4 (de)
AU (1) AU2001231192A1 (de)
WO (1) WO2001055170A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1767656A3 (de) * 2001-10-30 2007-07-25 Ortho-Clinical Diagnostics, Inc. Methoden zur feststellung und behandlung von leukämie
BR0206251A (pt) * 2001-10-30 2004-06-15 Ortho Clinical Diagnostics Inc Métodos para avaliar e tratar leucemia
AU2003240446A1 (en) * 2002-04-03 2003-10-13 Novartis Ag Use of mob-5 in pain
MXPA06006377A (es) * 2003-12-03 2006-08-23 Schering Corp Metodos para modular la actividad de citocina y reactivos relacionados.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011986A1 (en) * 1993-10-27 1995-05-04 The Trustees Of Columbia University In The City Of New York METHOD FOR GENERATING A SUBTRACTED cDNA LIBRARY AND USES OF THE GENERATED LIBRARY
WO1999064576A2 (en) * 1998-06-10 1999-12-16 Bayer Corporation Human genes differentially expressed in colon cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011986A1 (en) * 1993-10-27 1995-05-04 The Trustees Of Columbia University In The City Of New York METHOD FOR GENERATING A SUBTRACTED cDNA LIBRARY AND USES OF THE GENERATED LIBRARY
WO1999064576A2 (en) * 1998-06-10 1999-12-16 Bayer Corporation Human genes differentially expressed in colon cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHIA SOO ET AL: "CUTANEOUS RAT WOUNDS EXPRESS C49A A NOVEL GENE WITH HOMOLOGY TO THEHUMAN MELANOMA DIFFERENTIATION ASSOCIATED GENE MDA-7", JOURNAL OF CELLULAR BIOCHEMISTRY, WILEY-LISS INC, US, vol. 74, AF004774, 1 July 1999 (1999-07-01), pages 1 - 10, XP000943248, ISSN: 0730-2312 *
DATABASE EMBL [online] 11 September 1997 (1997-09-11), "Rattus norvegicus c49a mRNA, complete cds", XP002237763, Database accession no. AF004774 *
DATABASE EMBL [online] 31 December 1995 (1995-12-31), "Human MDA-7 mRNA, complete cds", XP002237765, Database accession no. U16261 *
DATABASE SWALL [online] 1 November 1997 (1997-11-01), "Interleukin-24 precursor (MDA-7)", XP002237766, Database accession no. Q13007 *
DATABASE SWALL [online] 1 November 1999 (1999-11-01), "C49a", XP002237764, Database accession no. Q9WVP8 *
JIANG H ET AL: "SUBTRACTION HYBRIDIZATION IDENTIFIES A NOVEL MELANOMA DIFFERENTIATION ASSOCIATED GENE, MDA-7, MODULATED DURING HUMAN MELANOMA DIFFERENTIATION, GROWTH AND PROGRESSION", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 11, no. 12, Q13007, 21 December 1995 (1995-12-21), pages 2477 - 2486, XP002064717, ISSN: 0950-9232 *
JO HAKRYUL ET AL: "Cloning oncogenic Ras-regulated genes by differential display.", METHODS (ORLANDO), vol. 16, no. 4, December 1998 (1998-12-01), pages 365 - 372, XP002237762, ISSN: 1046-2023 *
LIANG P ET AL: "RAS ACTIVATION OF GENES: MOB-1 AS A MODEL", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 91, December 1994 (1994-12-01), pages 12515 - 12519, XP002928076, ISSN: 0027-8424 *
See also references of WO0155170A1 *

Also Published As

Publication number Publication date
WO2001055170A1 (en) 2001-08-02
AU2001231192A1 (en) 2001-08-07
EP1254155A1 (de) 2002-11-06
WO2001055170A9 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
PL346262A1 (en) Stripable varnishes
AU2001233626A1 (en) Marker
GB2374046B (en) Marker pens
EP1277472A4 (de) Heilmittel für krebs
EP1319403A4 (de) Mittel gegen cisplatin-toleranten krebs
AU2001282149A1 (en) Improved marker
GB0117790D0 (en) Diagnostic marker
EP1254155A4 (de) Mob-5/hmob-5 als diagnostisches markierungsmittel
AU5513001A (en) A cannula assembly
GB2366712B (en) Planter
IL146525A0 (en) Marker
HK1041455A1 (zh) 一種癌症溫熱療法設備
GB0102480D0 (en) Marker
GB0427771D0 (en) Diagnostic marker
GB0016690D0 (en) Eplthelial diagnostic aid
GB0031166D0 (en) Tumour Marker
GB0006695D0 (en) Breast cancer markers
PL111677U1 (en) Marker
PL111676U1 (en) Marker
GB0005466D0 (en) Cancer
GB0122410D0 (en) Cancer diagnosis
GB0027048D0 (en) Shield
GB0015090D0 (en) Gene-activating conjugates
GB0124799D0 (en) Distance marker
GB0008475D0 (en) Depth marker

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020826

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030506

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081213